Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis c virus infection

Gut and Liver

Volumn 7, Issue 1, 2013, Pages 82-88

  Oguz, Ayten ^a   Atay, Ahmet Engin ^b   Tas, Adnan ^c   Seven, Gulseren ^d   Koruk, Mehmet ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

^c Osmaniye Public Hospital   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

Author keywords

Acute phase proteins; Hepatitis C; Hepatitis C virus RNA

Indexed keywords

ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA 2 MACROGLOBULIN; ANTIVIRUS AGENT; C REACTIVE PROTEIN; FERRITIN; OROSOMUCOID; TRANSFERRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MALE; PREDICTION; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 84875085915     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.1.82     Document Type: Article

References (43)

1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(5 Suppl):S30-S34.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095-2100.
4. Radziewicz H, Ibegbu CC, Hon H, et al. Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. J Immunol 2010;184:2410-2422.
5. Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736.
6. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
7. Valenti L, Pulixi EA, Arosio P, et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007;92:1037-1042.
8. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994;39:2426-2432.
9. Tiggelman AM, Boers W, Moorman AF, et al. Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas. Hepatology 1996;23:1260-1267.
10. Jang JY, Chung RT. Chronic hepatitis C. Gut Liver 2011;5:117-132.
11. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002;36(5 Suppl):S114-S120.
12. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008;48:80-87.
13. Ait-Goughoulte M, Banerjee A, Meyer K, et al. Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response. Hepatology 2010;51:1505-1513.
14. Akkus I, Gurbilek M, Caglayan O. Clinical biochemistrical laboratory handbook. Istanbul: Oz Egitim Basm Yayn Dagtm Ltd. Sti., 1997;15-55.
15. Tsui JI, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail 2009;15:451-456.
16. Bourliere M, Penaranda G, Ouzan D, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008;28:458-467.
17. Jang JY, Chung RT. Chronic hepatitis C. Gut Liver 2011;5:117-132.
18. Shima M, Nakao M, Kato Y, et al. Comparative study of C-reactive protein in chronic hepatitis B and hepatitis C. Tohoku J Exp Med 1996;178:287-297.
19. Atono Y, Sata M, Tanikawa K. Kinetics of C-reactive protein in acute viral hepatitis. Gastroenterol Jpn 1989;24:655-662.
20. Huang CF, Hsieh MY, Yang JF, et al. Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Hepatol Int 2010;4:621-627.
21. Biro L, Varga L, Par A, et al. Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b. Immunol Lett 2000;72:69-74.
22. Ono K, Sata M, Murashima S, Fukuizumi K, Suzuki H, Tanikawa K. Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res 1996;20:1560-1563.
23. Lapinski TW. Activation of acute phase proteins in patients with chronic hepatitis C treated with interferon-alpha 2a. Pol Merkur Lekarski 2001;10:138-142.
24. Bolewska B, Wojtacha A, Juszczyk J, Przedwojewski M. Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment. Pol Merkur Lekarski 2005;18:552-555.
25. Stam TC, Swaak AJ, Kruit WH, Eggermont AM. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur J Clin Invest 2002;32 Suppl 1:79-83.
26. Mozer-Lisewska I, Mania A, Kowala-Piaskowska A, Figlerowicz M, Sluzewski W. Alterations of soluble transferrin receptor level in children with chronic hepatitis C during treatment with recombinant interferon-alpha and ribavirin. Hepatol Res 2005;33:19-23.
27. Martin-Vivaldi R, Nogueras F, Gonzalez A, et al. Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolism. Rev Esp Enferm Dig 1997;89:523-530.
28. Casaril M, Stanzial AM, Tognella P, et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000;47:220-225.
29. Bayraktar Y, Saglam F, Temizer A, Uzunalimodlu B, van Thiel DH. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Hepatogastroenterology 1998;45:2322-2327.
30. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 2003;37:795-801.
31. Hofer H, Osterreicher C, Jessner W, et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004;40:1018-1022.
32. Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol 2004;99:286-291.
33. Arber N, Moshkowitz M, Konikoff F, et al. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection. Dig Dis Sci 1995;40:2431-2433.
34. Kalabay L, Nemesanszky E, Csepregi A, et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. Int Immunol 2004;16:51-54.
35. Weiss G, Umlauft F, Urbanek M, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999;180:1452-1458.
36. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
37. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-942.
38. Feher J, Jakab L, Jozsa L, Szilvasi I, Papp G. Serum immunoglobulin and glycoprotein concentration and mesenchymal reaction in chronic hepatitis and liver cirrhosis. Morphol Igazsagugyi Orv Sz 1977;17:180-186.
39. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-133.
40. Ho AS, Cheng CC, Lee SC, et al. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010;17:58.
41. Anderson S, Nevins CL, Green LK, El-Zimaity H, Anand BS. Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection. Dig Dis Sci 2001;46:1393-1398.
42. Luo JC, Hwang SJ, Chang FY, et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology 2002;49:478-481.
43. Volchkova EV, Pak SG, Malov VA, Umbetova KT. Changes in the levels of acute phase proteins in viral hepatitis. Ter Arkh 2000;72:18-21.